Epistem Share Discussion Threads

[the ghost who walks] 31/12/2015 15:15

Executives piling in

[azzi] 28/10/2015 15:32

Unfortunately I have read the briefing note a few times now and believe they have some very deep problems with the flagship technology right now. I understand the care needed to message the city, however in this instance you don`t have to read too much between the lines to recognise that EHP will need more time and more cash to get themselves back on track. In fairness to the interim CEO, he appears to have made some honest remarks which is refreshing to see.

[bigman] 28/10/2015 14:10

SHAMBLES is correct... Aziz... the chairman and CEO have departed and left others to try to rescue something from this SHAMBLES... £4m operating loss... no wonder Walls went with a big bag of cash... grabbed it before none left methinks... raised £4.7M in bonds and over £4m in bank at start of financial year... now there is £4.9M left ( well a lot less i guess after paying off Mr Walls the CEO who I presume got his crazy contract paid up) So just enough cash to see through this year.... but don't hold out much hope for any fund raising so the writing is on the wall.... maybe another strategic revue is required as in another of David Evans companies EKF which also appears to have hit a few problems. got to say i wish the new CEO/Chairman well and hope he can rescue something..

[pugugly] 28/10/2015 08:13

Results out - Not (IMO) very encouraging - In fact down right worry -

I have been following form pre IPO but have never invested as technology promise seemed to good to be true - On the surface no reason to change my mind.

anyone who thinks I may be wrong please advise why

[bigman] 26/10/2015 11:56

agree entirely azzi..... i see announced matthew walls resignation from the board today...... yet announced in august he was no longer ceo...... methinks last couple of months negotiating his package to depart. or why else did he not go in august rather strange.

[azzi] 26/10/2015 09:01

No longer an investor, but still keep watching. If all was OK with the technology we should have received an update following the Indian launch by now. I still think something is fundamentally wrong with the technology, if so, I think investors past and present deserve some honest messaging.

[bigman] 23/10/2015 13:48

is there any hope at all for this ?...... I think not

[the ghost who walks] 14/8/2015 15:35

Thanks Azzi for the update on your thougts and whether or not to reinvest. Good luck with your future investments.

[buywell3] 14/8/2015 15:19

Cheer up

''Take that you swine''



''how many more in there ?''

[azzi] 14/8/2015 15:16

Ghost, I have been an EHP supporter for years but I clearly gauged the prospect incorrectly - my mistake. Through my own findings and conclusions I have decided not to re-invest, I may well be wrong again, however I have made my decision.
End.

[the ghost who walks] 14/8/2015 10:08

Azzi, then on the Point on proving itself in the field, no one knows this yet do we as its only just started being tested. That you don't know this is therefore no surprise.

[the ghost who walks] 14/8/2015 10:04

Ok but that is a different argument to the point about technologies. If you look on google you can probably find some more info on genedrive which it may be worth looking into next time.

[azzi] 14/8/2015 09:56

Yes there are some significant differences - I do not know the pricing strategy employed by EHP. As I mentioned , my concern is whether the EHP technology is really proving itself in the field. I anticipated a raft of positive news flow at this time, maybe it is too soon, however the share price decline and sudden departure of the CEO isn`t positive.

[buywell3] 14/8/2015 09:49

Losing your CEO is a pretty important event

The setting on of a Temp CEO means no decent replacement could be found or wanted in

With the chart and losses pending I am not surprised

[the ghost who walks] 14/8/2015 09:42

From your source azzi: Some concerns have been raised about the Xpert MTB/RIF, including minor operational issues and cost. The concessional price for a GeneXpert system is currently USD 17,000 for a four module instrument.

[the ghost who walks] 14/8/2015 09:34

Thanks azzi. Those devices you mentioned are quite different, notably in cost, power source supply (which determines where it can be used) etc etc. but thanks for the update.

[azzi] 14/8/2015 08:34

Ghost, I should add that I invested in EHP several years ago. I believed the claims and the story. However, as you will see, even a limited amount of research highlights that EHP are playing in an increasingly crowded market for molecular biology MTB testing. My big, big,worry is that genedrive is not performing as expected.

[azzi] 14/8/2015 08:21

Ghost - Well to start with Luminex/Cepheid and GenXpert, these received WHO approval for Tb in 2010. Simply search "GeneXpert MTB/RIF" in Wikipedia for starters - I assume all investors conduct such searches as a matter of routine.
You will see that it is a direct competitor to EHP - sure there are differences but their technology has been in the market for nearly 5 years already - there is nothing novel about MTB/RIF testing!
Once you have researched some of the valuable references cited, take a look at the WHO site and search under TB and you will find many more companies playing in the same field - it should be an eye opener.

[the ghost who walks] 13/8/2015 17:30

Auto correct - azzi rather than aside

[the ghost who walks] 13/8/2015 17:30

Aside, could you share the names of competitors which are you say leaving genedrive behind so I can look into them, or post your full research ideally. Thanks

[buywell2] 13/8/2015 16:51

Long term support broken


free stock charts from uk.advfn.com

[buywell3] 13/8/2015 16:38

The chart of this company is dire


It says it all about timing ones investment


Getting in before profits are made is very, very risky


Getting in just before they are due to go into profit is the best


Long support has been recently broken


free stock charts from uk.advfn.com

[bigman] 13/8/2015 08:30

Azzi, excellent post and good to see someone doing their homework. Am afraid this company has blown it and time will eventually see it demise to a market cap of a few £m. It has promised and promised for years since coming to the market with hype and delivered nothing but losses and raised many millions to fund them, repeatedly promising tomorrow whilst the directors and in particular Walls the CEO filled his boots with huge salaries and big bonuses, he knew what he was doing all the time which is why out of £300k salary he invested NOTHING, not a bean in buying shares. that says it all.

[azzi] 12/8/2015 09:19

I still monitor EHP after selling out at a loss some months ago. I stated that something wasn`t quite right with the company, I think recent events and the share price confirms this. As I have watched the decline in the sp, I have been doing some digging to find out what the prospects of the flagship product, Genedrive, really is. After all there could still be a chance to re-invest for a profit!
Unfortunately I am concluding that Genedrive is just another testing platform among an ever growing battery of molecular diagnostic devices. I worry that problems with the technology (as mentioned in Mathew Walls updates over the past 18 months)indicate fundamental weaknesses with both performance and reliability. This would explain the non existing take up in India so far. We were led to believe that Genedrive was a "disruptive" technology that would transform point of care testing - sorry, but I think EHP are being left behind, their competitors in the field are possibly years ahead of them, yet still those competitors struggle to gain traction in India. Possibly we are missing something - we know TB is endemic in parts of India, the existing testing regimes prove this, however, do the government have the resources to fund the best treatments for all those affected? I have it on good authority that they don`t. So what real benefits does a rapid test provide in India? I am applying this rationale to many other models globally and coming up with the same conclusion.
I thinks Bigmans atatement, "the Emperors new clothes" sums it up.
My recent and current searches on EPH have found nothing positive at all at a time when I would argue positive news flow should be accelerating.
I have followed the company for years and will continue to do so. however, no more green from me.
Azzi